Cover Image
市場調查報告書

T細胞特定表面醣蛋白 CD28:開發中產品分析

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 366663
出版日期 內容資訊 英文 49 Pages
訂單完成後即時交付
價格
Back to Top
T細胞特定表面醣蛋白 CD28:開發中產品分析 T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H1 2017
出版日期: 2017年06月13日 內容資訊: 英文 49 Pages
簡介

本報告提供以T細胞特定表面醣蛋白 為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊CD28。

簡介

  • 調查範圍

T細胞特定表面醣蛋白 CD28 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Atox Bio Ltd.
  • Bristol-Myers Squibb Company
  • OSE Immunotherapeutics
  • TheraMAB LLC

藥物簡介

暫停中的計劃

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0816TDB

Summary

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - CD28 is a proteins expressed on T cells. It co-stimulates signals required for T cell activation and survival. It enhances the production of IL4 and IL10 in T-cells in conjunction with TCR/CD3 ligation and CD40L co-stimulation.

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) pipeline Target constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 2 and 2 respectively. Report covers products from therapy areas Immunology, Oncology, Central Nervous System, Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Metabolic Disorders, Musculoskeletal Disorders, Ophthalmology and Toxicology which include indications Graft Versus Host Disease (GVHD), Rheumatoid Arthritis, Systemic Lupus Erythematosus, Acute Renal Failure (ARF) (Acute Kidney Injury), Arthritis, B-Cell Chronic Lymphocytic Leukemia, Gastrointestinal Radiation Toxicity, Hypersensitivity, Kidney Transplant Rejection, Multiple Sclerosis, Pancreatitis, Plaque Psoriasis (Psoriasis Vulgaris), Psoriasis, Sicca Syndrome (Sjogren), Skin And Soft Tissue Infections, Solid Tumor, Type 1 Diabetes (Juvenile Diabetes) and Uveitis.

The latest report T Cell Specific Surface Glycoprotein CD28 - Pipeline Review, H1 2017, outlays comprehensive information on the T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviewsalso reviews key players involved in T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)
  • The report reviews T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics and enlists all their major and minor projects
  • The report assesses T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Overview
    • T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
  • T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Companies Involved in Therapeutics Development
    • Atox Bio Ltd
    • Bristol-Myers Squibb Company
    • Five Prime Therapeutics Inc
    • OSE Immunotherapeutics
    • TheraMAB LLC
  • T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Drug Profiles
    • ALPN-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FPT-155 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FR-104 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lulizumab pegol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Agonize CD278 and CD28 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Agonize CD278 and CD28 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • reltecimod sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAB-08 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Dormant Products
  • T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Discontinued Products
  • T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Product Development Milestones
    • Featured News & Press Releases
      • May 23, 2017: Atox Bios Reltecimod Passes Futility Analysis in Phase 3 ACCUTE Study; Trial Continues as Planned
      • Nov 17, 2016: OSE Immunotherapeutics announces the online publication of positive Phase 1 clinical results with FR104 in the Journal of Immunology
      • Nov 03, 2016: Atox Bio Announces Independent Safety Monitoring Committee Recommendation to Continue Phase 3 Study Of AB103 In Necrotizing Soft Tissue Infections
      • Jun 15, 2016: Atox Bio Awarded Next Milestone-based Option by BARDA to Support Development of AB103 for Necrotizing Soft Tissue Infections
      • Dec 07, 2015: Atox Bio Enrolls First Patient in Phase 3 Study of Potential Treatment for Necrotizing Soft Tissue Infection (Flesh Eating Bacteria)
      • Jul 09, 2015: Effimune launches Phase I clinical trial on immune system regulation control
      • Apr 15, 2015: Effimune obtains regulatory approval for Phase I clinical trial in humans of its new immunomodulator FR104
      • Feb 12, 2015: Two major scientific articles validate Effimune's drug candidate and reinforce the proof of concept of the technology aimed at regulating the immune system
      • Dec 25, 2014: TheraMAB presents new clinical data on theralizumab (TAB08) at Nature Biotechnology
      • Sep 29, 2014: Atox Bio Awarded Contract Worth up to $24 Million for the Development of AB103 by the Biomedical Advanced Research and Development Authority
      • Aug 05, 2014: AB103 Granted Orphan Medicinal Product Designation in the European Union for the Treatment of Necrotizing Soft Tissue Infections
      • Jan 14, 2014: TheraMAB announces initiation of Phase II clinical trial of mAb TABO8 for the treatment of Rheumatoid Arthritis
      • Apr 09, 2013: Atox Bio Publishes Data Demonstrating Broad Therapeutic Effect Of Flagship Product In Treating Flesh Eating Bacteria
      • Nov 20, 2012: Atox Bio Announces Positive Top-line Results In AB103 Necrotizing Soft Tissue Infections Phase IIa Trial
      • Sep 10, 2012: Atox Bio's AB103 Receives FDA Fast Track Designation For Treatment Of Necrotizing Soft Tissue Infections
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Indication, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Pipeline by Atox Bio Ltd, H1 2017
  • Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Pipeline by Five Prime Therapeutics Inc, H1 2017
  • Pipeline by OSE Immunotherapeutics, H1 2017
  • Pipeline by TheraMAB LLC, H1 2017
  • Dormant Projects, H1 2017
  • Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Top 10 Indications, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top